Lonza Group (LONN) Investor Update summary

Strategic vision and organizational transformation

• Introduced the 'One Lonza' vision, emphasizing a unified strategy and culture to drive value creation, operational excellence, and leadership in the CDMO industry.

• Launched the 'Lonza Engine' as a framework for leveraging core strengths, focusing on high-performance teams, scientific ecosystem, customer partnerships, execution excellence, and scalable growth.

• Announced a major organizational reshaping into three business platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities, removing the business unit layer for scalability and efficiency.

• Decided to exit the CHI (Capsules and Health Ingredients) business, citing limited synergy with core CDMO activities, with divestment process to begin in 2025.

• Leadership changes and deep CEO engagement implemented to align with new business platforms and support the transition.

Market outlook and growth strategy

• CDMO market expected to grow 8-10% annually, with the company targeting an additional 2-3% above market through its differentiated model.

• Growth driven by increasing outsourcing from pharma to CDMOs, especially in biologics, with CDMOs projected to handle 55% of capacity by 2029.

• Balanced customer base with a 50:50 revenue split between Big Pharma and Biotech, and high customer retention.

• Focus on early-stage partnerships and supporting 900 new molecules at any time to stay ahead in technology and innovation.

• Ongoing investments in capacity, technology, and talent, including the Vacaville site acquisition and expansion of global sites.

Financial model and guidance update

• New financial framework centers on organic growth, targeting low-teens average annual sales growth and Core EBITDA margin approaching 30%.

• CapEx to remain in the mid- to high-teens % of sales for base infrastructure, and low-teens % for growth projects.

• 2024 guidance confirmed: flat CER sales growth, Core EBITDA margin 27-29%.

• 2025 CDMO business expected to deliver CER sales growth approaching 20%, including CHF 500 million from Vacaville, with margin further approaching 30%.

• CHI business to be guided separately from 2025, with low- to mid-single-digit CER sales growth and mid-20s% Core EBITDA margin.